- Home
- PALI vs VNDA Comparison
PALI vs VNDA Comparison
Compare PALI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- VNDA
- Stock Information
- Founded
- PALI 1996
- VNDA 2002
- Country
- PALI United States
- VNDA United States
- Employees
- PALI N/A
- VNDA N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- VNDA Health Care
- Exchange
- PALI Nasdaq
- VNDA Nasdaq
- Market Cap
- PALI 212.0M
- VNDA 249.4M
- IPO Year
- PALI N/A
- VNDA 2006
- Fundamental
- Price
- PALI $1.96
- VNDA $4.50
- Analyst Decision
- PALI Strong Buy
- VNDA Strong Buy
- Analyst Count
- PALI 2
- VNDA 2
- Target Price
- PALI $12.00
- VNDA $15.50
- AVG Volume (30 Days)
- PALI 10.3M
- VNDA 674.7K
- Earning Date
- PALI 11-11-2025
- VNDA 10-29-2025
- Dividend Yield
- PALI N/A
- VNDA N/A
- EPS Growth
- PALI N/A
- VNDA N/A
- EPS
- PALI N/A
- VNDA N/A
- Revenue
- PALI N/A
- VNDA $212,074,000.00
- Revenue This Year
- PALI N/A
- VNDA $15.45
- Revenue Next Year
- PALI N/A
- VNDA $37.82
- P/E Ratio
- PALI N/A
- VNDA N/A
- Revenue Growth
- PALI N/A
- VNDA 11.12
- 52 Week Low
- PALI $0.53
- VNDA $3.81
- 52 Week High
- PALI $3.44
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- PALI 61.09
- VNDA 31.70
- Support Level
- PALI $1.61
- VNDA $4.32
- Resistance Level
- PALI $2.14
- VNDA $5.70
- Average True Range (ATR)
- PALI 0.17
- VNDA 0.22
- MACD
- PALI -0.01
- VNDA -0.13
- Stochastic Oscillator
- PALI 70.09
- VNDA 4.71
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.